Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sosei buys stake in RNA therapy firm

by Michael McCoy
May 8, 2017 | A version of this story appeared in Volume 95, Issue 19

Japan’s Sosei Group will spend $45 million to acquire a 25.6% ownership stake in MiNA Therapeutics and an option to potentially acquire all of the London-based firm. MiNA’s lead compound is MTL-CEBPA, a small activating RNA that is in the midst of Phase I/IIa clinical trials as an advanced liver cancer treatment. Sosei says MiNA will complement Heptares Therapeutics, a London-based developer of drugs targeting G protein-coupled receptors that Sosei acquired in 2015.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.